Optic neuropathy: case reportIn a report of the proceedings of the 42 nd Annual and First Virtual Upper Midwest Neuro-Ophthalmology Group Meeting conducted on 24 July 2020, a 58-year-old man was described, who developed optic neuropathy during treatment with hydroxychloroquine for suspected COVID-related infection.The man, who had been taking hydroxychloroquine [route and dosage not stated] for a suspected COVID-related infection, presented with bilateral blurred vision and dyschromatopsia (without any associated pain on eye movements). Ocular exam was unremarkable, and the optical coherence tomography macula was normal; however, he was found to have ganglion cell layer loss in both the eyes. He tested negative for COVID-19 PCR and antibodies. MRI was also unremarkable. He received unspecified steroids, to which he did not respond. Also, Leber's hereditary optic neuropathy point mutation testing was noted to be negative, and he had normal levels of nutritional optic neuropathy-associated vitamin. Based on the exclusion of alternative potential aetiologies and the temporal association, he was noted to have hydroxychloroquine-associated optic neuropathy as the likely culprit for presentation [duration of treatment to reaction onset and outcome of not stated].